Retifanlimab
Non-Small Cell Squamous Lung Carcinoma
Explore 53 assets in Non-Small Cell Squamous Lung Carcinoma →Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Incyte Corporation
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
48Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04205812CT.gov Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Non-Small Cell Squamous Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Retifanlimab (this asset) | Incyte Corporation | P3 | B · 63 |
| Carboplatin | Gruppo Oncologico Italiano di Ricerca Clinica | P3 | BBB |
| Pembrolizumab | Shanghai Henlius Biotech | P3 | BB |
| Serplulimab | Shanghai Henlius Biotech | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | Gruppo Oncologico Italiano di Ricerca Clinica | P3 | BB |
| Docetaxel | Shanghai Henlius Biotech | P3 | BB |
| Tislelizumab | BeOne Medicines | P3 | BB |
| Catequentinib | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | P3 | BB |
| Olaparib | Merck Sharp & Dohme LLC | P3 | BB |
+42 more in the Non-Small Cell Squamous Lung Carcinoma cohort
Other indications for Retifanlimab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Anal Canal Squamous Cell Carcinoma | — | P3 | BB · 66 |
| Urothelial Carcinoma | — | P2 | BB · 66 |
| Renal Cell Carcinoma | — | P2 | B · 63 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Retifanlimab in Non-Small Cell Squamous Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/retifanlimab-non-small-cell-squamous-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →